Pertento Partners’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-3,104,361
Closed -$35M 21
2025
Q2
$35M Sell
3,104,361
-520,252
-14% -$5.64M 3.13% 16
2025
Q1
$36.6M Buy
3,624,613
+139,695
+4% +$1.51M 3.83% 16
2024
Q4
$41.2M Buy
3,484,918
+646,865
+23% +$7.65M 3.49% 15
2024
Q3
$32.8M Buy
2,838,053
+185,491
+7% +$2.11M 3.61% 15
2024
Q2
$28M Buy
2,652,562
+824,499
+45% +$9.04M 2.83% 15
2024
Q1
$19.3M Buy
1,828,063
+948,849
+108% +$10.2M 3.56% 13
2023
Q4
$9.87M Buy
+879,214
New +$8.57M 1.66% 19

Other funds holding ROIV

Pertento Partners's ROIV Position: Q3 2025 in Review

Pertento Partners sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 3,104,361 shares — an estimated $35M sold.

Pertento Partners first reported a position in ROIV in Q4 2023 and held it in 7 quarters. The position peaked at $41.2M in Q4 2024. 337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

  • Pertento Partners reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
  • Pertento Partners sold 3,104,361 Roivant Sciences shares in Q3 2025, an estimated $35M.
  • Pertento Partners first reported a position in Roivant Sciences in Q4 2023 and held it in 7 quarters.
  • Pertento Partners's Roivant Sciences position peaked at $41.2M in Q4 2024.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Pertento Partners's 13F filing for Q3 2025, filed 13 Nov 2025.